Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: A case series

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 12, 2009, Pages 1347-1350

  Kamalaporn, Patarapong ^a   Saravanan, Ramasamy ^a   Cirocco, Maria ^a   May, Gary ^a   Kortan, Paul ^a   Kandel, Gabor ^a   Marcon, Norman ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angiodysplasias; Gastrointestinal bleeding; Thalidomide

Indexed keywords

THALIDOMIDE;

ADULT; AGED; ANGIODYSPLASIA; ARTICLE; BLOOD TRANSFUSION; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; PERIPHERAL NEUROPATHY; PILOT STUDY; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANGIODYSPLASIA; ANGIOGENESIS INHIBITORS; BLOOD TRANSFUSION; CHRONIC DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 76749171642     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32832c9346     Document Type: Article

References (15)

1. Gordon FH, Watkinson A, Hodgson H. Vascular malformations of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2001; 15: 41-58.
2. Rogers BH. Endoscopic diagnosis and therapy of mucosal vascular abnormalities of the gastrointestinal tract occurring in elderly patients and associated with cardiac, vascular, and pulmonary disease. Gastrointest Endose 1980; 26: 134-138.
3. Junquera F, Saperas E, de Torres I, Vidal MT, Malagelada JR. Increased expression of angiogenic factors in human colonic angiodysplasia. Am J Gastroenterol 1999; 94: 1070-1076.
4. Boley SJ, DiBiase A, Brandt LJ, Sammartano RJ. Lower intestinal bleeding in the elderly. Am J Surg 1979; 137: 57-64.
5. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53: 609-612.
6. Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA, Meyer RM, et al. Hematology disease site group of the cancer care Ontario program in evidence-based care. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 2008; 34: 442-452.
7. Walker SL, Waters MF, Lockwood DN. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007; 78: 197-215.
8. Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin Rheumatol 2008; 27: 373-375.
9. Van de Poel MH, Pasman PC, Schouten HC. The use of thalidomide in chronic refractory graft versus host disease. Neth J Med 2001; 59: 45-49.
10. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-1277.
11. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. W Engl J Med 1997; 336: 1487-1493.
12. Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 2002; 50: 196-200.
13. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91: 4082-4085.
14. Dabak V, Kuriakose P, Kamboj G, Shurafa M. A pilot study of thalidomide in recurrent Gl bleeding due to angiodysplasias. Dig Dis Sci 2008; 53: 1632.
15. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al., for the Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. W Engl J Med 2007; 357: 2123-2132.